Testing ramucirumab with chemo for advanced small bowel cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding ramucirumab to chemotherapy (either paclitaxel or FOLFIRI) works better for advanced small bowel adenocarcinoma that has already been treated with certain prior medicines. It may help shrink tumors or slow cancer growth in people whose cancer has progressed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is confirmed as small bowel adenocarcinoma, and it is metastatic or not removable by surgery
- You have tried prior treatment that included 5-FU type chemo and/or oxaliplatin, and the cancer has progressed
- You are recovered from recent chemo/radiation (at least 14 days ago) and side effects are mild (mostly grade 1 or grade 2 numbness only)
- Recent scans and blood/urine tests meet key limits (for example, blood counts and liver/kidney numbers)
- Your general health is good enough for treatment (Zubrod performance status 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests three drugs together (futibatinib, paclitaxel, and ramucirumab) to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
This Phase 2 trial studies a combination of chemotherapy (carboplatin and a “taxane”) plus ramucirumab for people with advanced lung cancer that came back or progressed after prior maintenance treatment. It may help by attacking cancer growth after earlier therapy no longer worked.
This trial tests adding a new drug (zanidatamab) to standard chemotherapy (paclitaxel and ramucirumab) for people with advanced HER2-positive stomach, gastroesophageal junction, or esophageal cancer that has worsened after previous treatment. It aims to see if the combination works better.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) for people with advanced small bowel adenocarcinoma that cannot be surgically removed. It is for those who have not yet had treatment for their advanced cancer, except possibly one cycle of FOLFOX.
Hear when a new Metastatic Small Intestinal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.